You are here

INTERCEPT

89Bio Enlivened by Nash success

EP Vantage

Thu, 03/23/23 - 09:50 am

Akero Therapeutics

Madrigal Pharmaceuticals

Intercept Presents Data form Ph III Substudy That Supports Obeticholic Acid’s Ability to Reverse or Stabilize Fibrosis and Cirrhosis in Primary Biliary Cholangitis (PBC) Patients

CP Wire

Fri, 04/13/18 - 01:10 pm

primary biliary cholangitis

obeticholic acid

Intercept Presents Data form Ph III Substudy That Supports Obeticholic Acid’s Ability to Reverse or Stabilize Fibrosis and Cirrhosis in Primary Biliary Cholangitis (PBC) Patients

Fri, 04/13/18 - 12:53 pm

primary biliary cholangitis

obeticholic acid

OraSure Technologies and Roche Announce FDA 510(k) Clearance for Four Fully Automated Oral Fluid Drugs of Abuse Assays

Thu, 03/3/11 - 10:50 am

Adoption of Cerus' Technology Makes Its Valuation Look Ridiculous

Seeking Alpha

Tue, 02/9/10 - 10:54 am

Short Blood Supply Means Long Outlook for Cerus

Seeking Alpha

Sun, 11/15/09 - 06:16 pm